Immunotherapy of cancer: reprogramming tumor-immune crosstalk.
Immunotherapy of cancer: reprogramming tumor-immune crosstalk.
复制标题
癌症免疫疗法：重编程肿瘤免疫串扰。
DOI：
10.1155/2012/760965
复制
发表时间：
2012
影响因子：
--
通讯作者：
Manjili,MasoudH
中科院分区：
文献类型：
--
作者：
Payne,KyleK;Toor,AmirA;Wang,Xiang-Yang;Manjili,MasoudH
癌症免疫疗法的进步面临限制其疗效的障碍。这些包括肿瘤的弱免疫原性，以及阻止有效的抗肿瘤免疫反应的免疫抑制机制。最近的研究表明，癌症睾丸抗原（CTA）的异常表达可以产生强大的抗肿瘤免疫反应，这表明 CTA 是免疫治疗的潜在靶点。然而，肿瘤细胞在 CTA 表达的存在和数量方面的异质性导致肿瘤逃避 CTA 特异性免疫反应。因此，调节肿瘤细胞表观基因组以均匀诱导此类抗原表达的能力可能会使肿瘤更具免疫原性。此外，新兴研究表明，可以通过重新编程先天性和适应性免疫细胞来克服抗肿瘤免疫反应的抑制。因此，本文讨论了最近的研究，这些研究解决了成功癌症免疫治疗的障碍，并提出了一种调节肿瘤免疫细胞串扰的策略，以改善癌症患者的反应。
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs) can generate robust antitumor immune responses, which implicates CTAs as potential targets for immunotherapy. However, the heterogeneity of tumor cells in the presence and quantity of CTA expression results in tumor escape from CTA‐specific immune responses. Thus, the ability to modulate the tumor cell epigenome to homogenously induce expression of such antigens will likely render the tumor more immunogenic. Additionally, emerging studies suggest that suppression of antitumor immune responses may be overcome by reprogramming innate and adaptive immune cells. Therefore, this paper discusses recent studies which address barriers to successful cancer immunotherapy and proposes a strategy of modulation of tumor‐immune cell crosstalk to improve responses in carcinoma patients.